MHRA pulls Evertogen's GMP certificate after inspection

By Gareth Macdonald contact

- Last updated on GMT

Gettyimages/Ruskpp
Gettyimages/Ruskpp

Related tags: Tablet, Pharmacology, Regulation, Mhra

Evertogen Life Sciences Limited should recall drugs made at its facility in Mahabubnagar, India according to the MHRA, which identified critical quality and data integrity problems during an audit in August.

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) made the recommendation in a EudraGMDP notice​ last week, also confirming it has withdrawn Evertogen‘s certificate of good manufacturing practices (GMP) compliance.

The MHRA said, “A desktop inspection identified a critical deficiency in regard to the integrity of data, QC laboratory capability, cross contamination, a lack of senior management control and a failure of the quality system.

This was confirmed following an on-site inspection. Manufacturing personnel changed the method of manufacture without approval. Rejected in-process material was added to subsequent batches and excess discarded at packaging​.”

The UK regulator also raised concerns about “cross contamination events​,” in which “include rogue tablets, capsules, package inserts and blisters in cartons​” for one product were found in other products also made at the site.

In addition, the MHRA said QC personnel had reused sample data for unrelated batches, missed time points during stability testing and based risk assessments on pre-existing data.

The Mahabubnagar plant makes tablet and capsule based pharmaceutical products. Regulators in India, Canada, Ukraine, Australia and Kazakhstan have approved it to supply drugs according to Evertogen’s website.

Evertogen did not respond to a request for comment.

Related news

Related products

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us

Products

View more

Webinars